The myeloid differentiation factor 88 signaling in donor T cells accelerates graft-versus-host disease.
The myeloid differentiation factor 88 signaling has a crucial role in activation of both innate and adoptive immunity. Myeloid differentiation factor 88 transduces signal via Toll-like receptor and interleukin-1 receptor superfamily to NFkB pathway and inflammasome by forming a molecular complex with interleukin-1 receptor-associated kinase 4. Myeloid differentiation factor 88/interleukin-1 receptor-associated kinase 4 pathway plays an important role not only in innate immunity but also T-cell immunity; however, its role in donor T cells on graft-versus-host disease pathophysiology remains to be elucidated. We addressed this issue by using myeloid differentiation factor 88-deficient T cells in a mouse model of allogeneic hematopoietic stem cell transplantation. While myeloid differentiation factor 88-deficient and wild-type T cells proliferated equivalently after transplantation, myeloid differentiation factor 88-deficient T cells demonstrated impaired survival and differentiation toward Th1, Tc1, and Th17, and induced less severe graft-versus-host disease compared to wild-type T cells. Administration of interleukin-1 receptor-associated kinase 4 inhibitor PF-06650833 significantly ameliorated graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. These results thus demonstrate that donor T-cell myeloid differentiation factor 88/ interleukin-1 receptor-associated kinase 4 pathway is a novel therapeutic target against graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.